Michael Miller - Jazz Pharmaceuticals Senior Vice President - U.S. Commercial
| J7Z Stock | EUR 100.75 1.75 1.71% |
President
Mr. Michael P. Miller is the Executive Vice President, U.S. Commercial of Jazz Pharmaceuticals PLC. Mr. Miller was appointed our Executive Vice President, U.S. Commercial, as of May 2017 and served as our Senior Vice President, U.S. Commercial, from April 2014 until May 2017. From April 2010 to January 2014, Mr. Miller was Senior Vice President and Chief Commercial Officer of Vivus, Inc., a biopharmaceutical company. From February 2006 to April 2010, he served as Vice President, Sales and Marketing, leading the HER Family Oncology Franchise, of Genentech, Inc., a biotechnology company and wholly owned subsidiary of Roche Holding Ltd. From January 2003 to December 2005, Mr. Miller served as the Senior Vice President, Chief Commercial Officer of Connetics Corporationrationration, a specialty pharmaceutical company acquired by Stiefel Laboratories, Inc. Previously, from 1997 to 2001, he served as Vice President of the Urology Business Unit of ALZA Corporationrationration, a pharmaceutical company acquired by Johnson Johnson. Prior to 1997, Mr. Miller served 13 years in various sales and marketing positions at Syntex Corporationrationration, a pharmaceutical company acquired by Roche Holding Ltd. He currently serves as a director on the board of Puma Biotechnology, Inc., a biopharmaceutical company, and as a member of two nonprofit boards, the Leukemia and Lymphoma Society and the Zane Beadles Parade Foundation since 2017.
| Age | 61 |
| Tenure | 7 years |
| Professional Marks | MBA |
| Phone | 353 1 634 7800 |
| Web | https://www.jazzpharma.com |
Michael Miller Latest Insider Activity
Tracking and analyzing the buying and selling activities of Michael Miller against Jazz Pharmaceuticals stock is an integral part of due diligence when investing in Jazz Pharmaceuticals. Michael Miller insider activity provides valuable insight into whether Jazz Pharmaceuticals is net buyers or sellers over its current business cycle. Note, Jazz Pharmaceuticals insiders must abide by specific rules, including filing SEC forms every time they buy or sell Jazz Pharmaceuticals'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Michael Miller over two weeks ago Acquisition by Michael Miller of 2512 shares of LCNB at 13.87 subject to Rule 16b-3 | ||
Michael Miller over a month ago Disposition of 125 shares by Michael Miller of Digital Turbine at 5.35 subject to Rule 16b-3 | ||
Michael Miller over a month ago Insider Trading |
Jazz Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.053 % which means that it generated a profit of $0.053 on every $100 spent on assets. This is way below average. Jazz Pharmaceuticals' management efficiency ratios could be used to measure how well Jazz Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 12 records | PRESIDENT Age | ||
| David Pasieka | Algonquin Power Utilities | 60 | |
| Gregory Willis | Air Lease | 40 | |
| John Poerschke | Air Lease | 61 | |
| Carol Forsyte | Air Lease | 60 | |
| Alex Khatibi | Air Lease | 62 | |
| Grant Levy | Air Lease | 60 | |
| Mary DePalma | Air Lease | N/A | |
| Michael Snow | Algonquin Power Utilities | 56 | |
| George Trisic | Algonquin Power Utilities | 56 | |
| Kishore Korde | Air Lease | 49 | |
| Marc Baer | Air Lease | 54 | |
| Jie Chen | Air Lease | 55 | |
Management Performance
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 |
Jazz Pharmaceuticals plc Leadership Team
Elected by the shareholders, the Jazz Pharmaceuticals' board of directors comprises two types of representatives: Jazz Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Jazz. The board's role is to monitor Jazz Pharmaceuticals' management team and ensure that shareholders' interests are well served. Jazz Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Jazz Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Diane Schrick, Senior Director, Investor Relations | ||
| Matthew Young, CFO, Senior Vice President | ||
| Finbar Larkin, VP Operations | ||
| Iain McGill, Senior Vice President - Jazz Pharmaceuticals Europe and Rest of World | ||
| Rick Winningham, Independent Director | ||
| Peter Gray, Non-Executive Director | ||
| Katherine Littrell, Vice President - Investor Relations | ||
| Paul Treacy, Senior Vice President Technical Operations | ||
| Renee Gala, Ex CFO | ||
| Robert MD, Ex RD | ||
| Robert Iannone, Executive Vice President Research and Development | ||
| Karen Wilson, Vice President - Finance, Principal Accounting Officer | ||
| Seamus Mulligan, Independent Director | ||
| Russell Cox, Chief Commercial Officer, Executive Vice President | ||
| Karen Smith, Global Head of Research & Development and Chief Medical Officer | ||
| Neena JD, Ex Officer | ||
| George Eliades, Sr Officer | ||
| Paul Berns, Independent Director | ||
| Daniel Swisher, President COO | ||
| Anne ORiordan, Director | ||
| Suzanne Hooper, Executive Vice President General Counsel | ||
| Patricia Carr, VP Officer | ||
| Heather McSharry, Director | ||
| Michael Miller, Senior Vice President - U.S. Commercial | ||
| Andrea Flynn, VP Relations | ||
| Patrick Enright, Independent Director | ||
| Norbert Riedel, Director | ||
| Catherine Sohn, Director | ||
| Heidi Manna, VP Officer | ||
| Elmar Schnee, Independent Director | ||
| Kenneth OKeefe, Independent Director | ||
| Bruce Cozadd, Chairman of the Board, CEO |
Jazz Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Jazz Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 13.72 B | |||
| Shares Outstanding | 62.97 M | |||
| Shares Owned By Insiders | 2.52 % | |||
| Shares Owned By Institutions | 93.17 % | |||
| Price To Earning | 15.29 X | |||
| Price To Book | 3.49 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Jazz Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Jazz Pharmaceuticals' short interest history, or implied volatility extrapolated from Jazz Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Complementary Tools for Jazz Stock analysis
When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |